Valid for Submission
C34.92 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of unspecified part of left bronchus or lung. The code C34.92 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C34.92 might also be used to specify conditions or terms like adenocarcinoma of left lung, large cell carcinoma of left lung, large cell carcinoma of lung, primary malignant neoplasm of left lung or squamous cell carcinoma of left lung.
Unspecified diagnosis codes like C34.92 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.
The code C34.92 is linked to some Quality Measures as part of Medicare's Quality Payment Program (QPP). When this code is used as part of a patient's medical record the following Quality Measures might apply: Lung Cancer Reporting (biopsy/cytology Specimens) , Lung Cancer Reporting (resection Specimens).
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Adenocarcinoma of left lung
- Large cell carcinoma of left lung
- Large cell carcinoma of lung
- Primary malignant neoplasm of left lung
- Squamous cell carcinoma of left lung
Diagnostic Related Groups - MS-DRG Mapping
Convert C34.92 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C34.92 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
Quality Payment Program Measures
When code C34.92 is part of the patient's diagnoses the following Quality Measures apply and affect reimbursement. The objective of Medicare's Quality Measures is to improve patient care by making it more: effective, safe, efficient, patient-centered and equitable.
|Quality Measure||Description||Quality Domain||Measure Type||High Priority||Submission Methods|
|Lung Cancer Reporting (Biopsy/Cytology Specimens)||Pathology reports based on biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type or classified as non-small cell lung cancer not otherwise specified (NSCLC-NOS) with an explanation included in the pathology report.||Communication and Care Coordination||Process||YES||Claims, Registry|
|Lung Cancer Reporting (Resection Specimens)||Pathology reports based on resection specimens with a diagnosis of primary lung carcinoma that include the pT category, pN category and for non-small cell lung cancer (NSCLC), histologic type.||Communication and Care Coordination||Process||YES||Claims, Registry|
Information for Patients
Also called: Bronchogenic carcinoma
Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk.
Common symptoms of lung cancer include
- A cough that doesn't go away and gets worse over time
- Constant chest pain
- Coughing up blood
- Shortness of breath, wheezing, or hoarseness
- Repeated problems with pneumonia or bronchitis
- Swelling of the neck and face
- Loss of appetite or weight loss
Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.
NIH: National Cancer Institute
- After chemotherapy - discharge (Medical Encyclopedia)
- Coughing up blood (Medical Encyclopedia)
- Lung cancer (Medical Encyclopedia)
- Lung cancer - non-small cell (Medical Encyclopedia)
- Lung cancer - small cell (Medical Encyclopedia)
- Lung PET scan (Medical Encyclopedia)
- Lung surgery (Medical Encyclopedia)
- Metastatic cancer to the lung (Medical Encyclopedia)
- Solitary pulmonary nodule (Medical Encyclopedia)
[Learn More in MedlinePlus]
Lung cancer Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent.Small cell lung cancer grows quickly and in more than half of cases the cancer has spread beyond the lung by the time the condition is diagnosed. Small cell lung cancer often metastasizes, most commonly to the liver, brain, bones, and adrenal glands (small hormone-producing glands located on top of each kidney). After diagnosis, most people with small cell lung cancer survive for about 1 year; less than seven percent survive 5 years.Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Adenocarcinoma arises from the cells that line the small air sacs (alveoli) located throughout the lungs. Squamous cell carcinoma arises from squamous cells that line the passages leading from the windpipe (trachea) to the lungs (bronchi). Large cell carcinoma arises from epithelial cells that line the lungs. Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. The 5-year survival rate for people with non-small cell lung cancer is usually between 11 and 17 percent; it can be lower or higher depending on the subtype and stage of the cancer.
[Learn More in MedlinePlus]